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HIGH RATE OF DE NOVO CHRONIC GRAFT-VERSUS-HOST (CGVHD)
FOLLOWING BUSULFAN-FLUDARABINE CONDITIONING AND ALLOGE-
NEIC STEM CELL TRANSPLANTATION FROM A MATCHED-SIBLING
DONOR (MSD) FOR AML/MDS
Saliba, R.M.1, Komanduri, K.V.2, Koca, E.1, Alousi, A.M.1, Giralt, S.1,
Andersson, B.S.1, Zhang, W.1, Rondon, G.1, Neumann, J.1,
Popat, U.R.1, Kebriaei, P.1, de Lima, M.1, Champlin, R.E.1 1University
of Texas MD Anderson Cancer Center, Houston, TX; 2University of Mi-
ami Sylvester Cancer Center, Miami, FL
Busulfan-fludarabine is increasingly used as a conditioning regi-
men for allogeneic stem cell transplantation (ASCT). Fludarabine
has complex immunologic effectswhichmay impact the development
of GVHD. Risk factors and outcomes of cGVHD in this setting have
not been determined. We retrospectively evaluated all consecutive
patients (pts) who received conditioning with IV Busulfan (130 mg/
m2 for 4 days) and Fludarabine (40 mg/m2 for 4 days) and ASCT
from a MSD at MD Anderson Cancer Center between 2001 and
2005. In a landmark analysis starting at day 1100, we estimated the
cumulative incidence (CI) of cGVHD (defined according to the re-
cent NIH consensus diagnostic criteria); evaluated risk factors for
overall and de novo cGVHD using Cox’s regression analysis; and eval-
uated the effect of cGVHDon outcome.104 pts were included in this
analysis. Median age was 46 years (12–65). 46% were females and
49% were in complete remission at the time of ASCT. Peripheral
blood (PB) was the stem cell source in 85% of pts. GVHD prophy-
laxis consisted of tacrolimus and methotrexate at standard doses.
The incidence of grade II-IV aGVHD was 18%. 89 pts were alive
on day 1100 without progression of their malignancy including 51
pts who had not developed aGVHD. With a median follow-up of
46 months in survivors, 57/89 pts developed cGVHD; half (n 5 29)
of these cases occurred de novo. The 3 years CI of de novo cGVHD
was 57% in the 51 pts without antecedent aGVHD. Time of onset
was later for de novo cGVHD compared with relapsing/progressive
cGVHD; median 195 days (115–693) vs. 143 days (100–639). The
use of PB was the only significant risk factor for development of
cGVHD (HRoverall5 3.3, P 0.01; HRde novo5 5.0, P 0.03). Recipient
age, recipient/donor sex andCMVserostatus, and disease status prior
to ASCT had no significant impact on the rate of cGVHD. On uni-
variate analysis considering cGVHD as time-dependent variable,
there was a trend toward an association of de novo cGVHD, but not
relapsing/progressive cGVHD, with a lower rate of disease progres-
sion (HR50.6,P0.4) andmortality (HR50.4,P0.1).Therewas also
a trend for more favorable overall survival (HR 5 0.4, P 0.08) and
non-relapse mortality (HR 5 0.3, P 0.2) in pts who developed de
novo compared with relapsing/progressive cGVHD. There is a high
frequencyof de novo cGVHDafter busulfan-fludarabine conditioning
and ASCT for AML/MDS. This suggests a shift in the epidemiology
of cGVHD that merits further consideration.340
EFFICIENT AND SELECTIVE PREVENTION OF GRAFT-VERSUS-HOST DIS-
EASE BY ANTIGEN-SPECIFIC TGF-INDUCED REGULATORY T CELLS
Semple, K.1,3, Iclozan, C.1, Anasetti, C.1,2, Yu, X.-Z.1,2,3 1H. Lee Moffitt
Cancer Center & Research Institute, Tampa, FL; 2University of South
Florida, Tampa, FL; 3University of South Florida, Tampa, FL
Naturally occurring regulatory T cells (nTregs) suppress the de-
velopment of graft-versus-host disease and may spare graft-versus-
tumor effect. As nTreg is a rare cell population in a healthy individ-
ual, using in vitro expanded nTregs is a common strategy to test their
therapeutic potential in hematopoietic cell transplantation (HCT).
However, the concern of in vitro expanded nTregs may include their
stability of Foxp3 expression and suppressive function, survival in
vivo, and non-selective suppression of pre-activated nTregs. In this
study, we have used an alternative strategy to generate antigen-spe-
cific, induced Tregs (iTregs). CD41CD25- cells from OT-II TCR
transgenic, foxp3/gfp knock-in mice were induced to express Foxp3
by incubating with OVA peptide in the presence of TGFb.
CD41GFP1 cells were purified by sorting and used as iTregs while
CD41GFP- cells as controls. Their ability to prevent GVHD was
tested in a lethally irradiated murine BMT model: B6 / (B6 x
bm12)F1. In order to evaluate the specificity of iTregs, OVA-
expressing or non-expressing F1 recipients were directly compared.We found that iTregs (CD41GFP1) efficiently prevented GVHD
lethality in OVA1 recipients at a Treg:Teff ratio up to 1:8. The ef-
ficacy of these antigen-specific iTregs were significantly higher than
polyclonal iTregs from B6 donors as the latter could only partially
prevent GVHD and prolong recipient survival even at a 1:1 ratio.
In contrast to OVA1 recipients, antigen-specific iTregs failed to
prevent GVHD in OVA- recipients. As controls, CD41GFP- cells
had no effect on GVHD development in OVA- recipients, and
even exacerbated GVHD in OVA1 recipients compared to B6
CD41 effector cells alone. These results reveal the therapeutic po-
tential of antigen-specific iTregs to prevent GVHD efficiently and
selectively.341
EXPLORING T-CELL RECRUITMENT DURING THE EARLIER PHASE OF
GRAFT VS. HOST DISEASE IN VITRO
Arditti, F.D., Goldgirsh, K., Friedman, T., Korngold, R. Hackensack Uni-
versity Medical Cente, Hackensack, NJ
Graft-versus-host disease (GVHD) is the major complication fol-
lowing allogeneic blood and marrow transplantation (BMT). Al-
though major advances have been achieved in understanding the
immunopathology of GVHD, the rate of success in the clinic has
been hampered by the inability to improve overall survival. T cell-
depletion of the hematopoietic stem cell inoculum has been proved
efficient in preventing GVHD, however, this treatment abolished
the graft-versus-leukemia (GVL) effect, also mediated by donor T
cells, resulting in significant increases in the rates of relapse. There-
fore, othermeans for separatingGVHDandGVLneed to be consid-
ered. Activation and recruitment of T cells to targeted organs during
GVHD is preceded by a well orchestrated, but yet unknown in
depth, sequence of events that involves the early secretion of chemo-
kines produced by a wide variety of cells, including dendritic cells,
mast cells, T cells and their primary targets duringGVHD, epithelial
cells, in the skin and the gastrointestinal tract. In this study, we take
advantage of our recently developed in vitro model of allogeneic T
cell/epithelial interactions to investigate this less explored aspect of
GVHD. Using a high throughput multicytokine assay, we examined
the secretion of different chemokines in cocultures of skin primary
epithelial cells (pEC), obtained from C.B10-H2b (BALB.B) mice,
with allogeneic T cells, derived from minor histocompatibility anti-
gen allogeneic C57Bl/6 (B6) mice. In addition to IFN-g and IL-12,
we detected the presence of MCP-1/CCL2, MIP-1a/CCL3,
RANTES/CCL5 and GM-CSF by 7 days after the addition of the
allogeneic T cells. Although we do not know yet in detail whether
T cells, epithelial cells, or both are responsible for the secretion of
the chemokines in our system, their level was dependent on the
amount of T cells added to the cocultures (p\0.03). However, we
found that in the absence of T cells, conditioning of the pEC by ex-
posure to 11 Gy of g-irradiation induced the secretion of 109.6 pg/
ml MCP-1 and 21.7 pg/ml RANTES within 24 hours. Thus, our
preliminary data suggests that the conditioning of epithelial cells,
alone, is enough to induce secretion of chemokines, which in turn
could induce T cell recruitment to the site before any damage to
the epithelial cells can be visualized, leading subsequently to an am-
plification cascade governed by chemokine secretion from both tar-
get and effector cells.342
WHAT IS THE ROLE FOR REGULATORY T-CELLS AFTER NONMYELOABLA-
TIVE CONDITIONING?
Humblet-Baron, S., Castermans, E., Vanbellighen, J.-F., Hannon, M.,
Jacobs, N., Willems, E., Ormenese, S., Beguin, Y., Baron, F. University
of Lie`ge, Lie`ge, Belgium
Purpose: We investigated the association between regulatory
T-cell (Treg) levels and chronic graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation (HCT)
following nonmyeloablative conditioning.
Methods: Data from 74 patients given nonmyeloablative condi-
tioning as treatment for hematological malignancies or renal cell
carcinomas were analyzed. Conditioning regimens consisted of
Poster Session-II 123low-dose TBI with (n 5 45) or without (n 5 17) fludarabine, or cy-
clophosphamide plus fludarabine (n 5 12). T-reg (CD41FoxP31)
levels on days 40, 100, 180 and 365 were determined by flow cytom-
etry. Chimerism levels among total white blood cells, CD31 T-cells
andCD41CD251CD127dim/neg regulatory T-cells were determined
by multiplex STR PCR or X-Y FISH. Thymic function was deter-
mined by assessing sjTREC levels.
Results:Mean Treg (6 SD) levels in controls were 316 18 cells/
mL.Mean (6 SD) Treg levels on day 100 were 206 24 cells /mL (p\
0.01 in comparison to controls) in patients without grade II-IV acute
GVHD before day 100, and 27 6 21 cells/mL (NS) in patients with
an antecedent of grade II-IV acute GVHD. Mean 6 donor CD31
T-cells and Treg chimerism levels on day 100 were 75 6 29% and
81 6 18%, respectively (NS). Day 100 chimerism levels among
CD31 T-cells and Tregs were highly correlated (r 5 0.78, p \
0.01). The 1-year probability of grade II-III NIH chronic GVHD
in patients with day 100 Treg levels below or above median was
53% and 36%, respectively (P 5 0.13). SjTREC levels significantly
increased from day 100 to day 365 after HCT (p\ 0.01), demon-
strating thymic recovery. Finally, Treg and sjTREC levels correlated
on days 100 (r 5 0.48, p\ 0.01) and 365 (r 5 0.47, p\ 0.01) after
HCT.
Conclusions: Our data did not show thus far a significant corre-
lation between Treg levels and occurrence of chronic GVHD. The
association between Treg and TREC levels on days 100 and 365
might suggest a role for the thymus in regulating Tregs levels after
HCT, or that similar factors affect thymic function and Treg levels
after nonmyeloablative conditioning. Data including higher number
of patients will be presented.343
GENERATION OF CLL-SPECIFIC CTL EFFECTORS FROM PARTIALLY HLA-
MATCHED UMBILICAL CORD BLOOD GRAFTS USING CD154-TRANS-
DUCED CLL CELL S AS APCS
Decker, W.K.1, Li, S.1, Xing, D.1, Robinson, S.N.1, Yang, H.1,
Steiner, D.1, Lapushin, R.2, Ramsay, A.G.3, Hosing, C.M.1,
Gribben, J.G.3, Keating, M.J.2, Shpall, E.J.1, Wierda, W.G.2 1Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX; 2University of
Texas MDAnderson Cancer Center, Houston, TX; 3Barts and the London
School of Medicine, London, United Kingdom
Introduction: Long-term remissions have been observed follow-
ing allogeneic hematopoietic stem cell transplantation (allo-HSCT)
for the treatment of chronic lymphocytic leukemia (CLL). Unfortu-
nately, many CLL patients are ineligible for transplant due to the
lack of an HLA-compatible donor. Umbilical cord blood (UCB)
HSCT permits transplantation of many individuals who are ineligi-
ble for allo-HSCTdue to its reduced requirement for stringentHLA
matching; however, disease relapse remains a significant complica-
tion. Further, unlike allo-HSCT, donor lymphocyte infusion
(DLI) cannot be employed as a post-transplant therapy. To address
this issue we are developing a strategy to generate CLL-specific
T-lymphocytes to be employed as a post-UCB-HSCT therapeutic
treatment.
Methods:CLL-specific antigen presenting cells (APC) were gen-
erated by the transduction of CLL cells with an adenoviral vector en-
coding CD154 (CD40L). Successful transduction and subsequent
CD40 ligation in CLL cells were verified by monitoring CD95 ex-
pression. CLL APCwere then used to prime partially HLAmatched
(typically 4/6) UCB lymphocytes in the presence of IL-12, IL-2,
IL-7, and IL-15. Expanded UCB lymphocytes were phenotyped by
flow cytometry, and CLL specificity was determined by ELISpot
and 51Cr lysis using non-CLL (CD19-/CD31) patient lymphocytes
as allo-antigen controls.
Results: Effector cell phenotype was predominantly (.80%)
CD41; however, skewing towardCD81 expansion could be achieved
by incubation in IL-12 during priming. Significant populations of ef-
fector memory (CD62L1CD1271) and central memory
(CD62L-CD1271) cells were observed following repeated stimula-
tions with CLL-APC. Significant expansion (.4 fold) of UCB lym-
phocyte populations was typically observed. In ELISpot assays,
CLL-APC primed UCB lymphocyte responders exhibited a signifi-
cant increase (p . 0.05) in IFN-g ELISpots when incubated with
CLL stimulators in comparison to non-CLL control stimulators.Cytolytic activity was demonstrated against unmodified CLL cells
by 51Cr release assays in which percent lysis of CLL targets was
30–50% at E:T ratios of 10:1 and 20:1. Lysis of autologous non-
CLL control targets was negligible.
Conclusions: Our results demonstrate that in vitro generation of
CLL-specific effectors from partially HLA-matched UCB lympho-
cytes is both feasible and practical. These preclinical results support
further exploration of this technique as a promising treatment mo-
dality in conjunction with UCB-HSCT.344
THE T CELL CYTOLYTIC MOLECULES FAS LIGAND AND TRAIL, THE TRAF-
FICKING MOLECULES CCR9, 7 INTEGRIN AND PSGL1, AND THE IMMUNE
MODULATING MOLECULES OX40 AND CEACAM1 ARE REQUIRED FOR
THYMIC GRAFT-VERSUS-HOST DISEASE
Lu, S.X., Na, I.-K., Goldberg, G.L., Ghosh, A., Hirschhorn-
Cymerman, D., King, C.G., Smith, O.M., Suh, D., Rao, U., Yim, N.,
Holland, A.M., Penack, O., Jenq, R.R., Teisch, L., Meykler, S., Lin, J.,
Sepulveda, A., Merghoub, T., Houghton, A.N., van den Brink, M.R.M.
Memorial Sloan-Kettering Cancer Center, New York, NY
Thymic graft-versus-host-disease (tGVHD) contributes to im-
paired T cell reconstitution after allogeneic bone marrow transplan-
tation, but its pathophysiology has not been well defined. We
assessed thymic output (RAG21 splenic recent thymic emigrants)
as well as the thymic cellularity (esp. CD41CD81 cells) and found
that these were inversely related to numbers of mature donor T cells
in the allograft. Bcl-2 expression in donor BM-derived thymocytes
was decreased in recipients with GVHD vs. those without GVHD,
which suggests that survival of thymocytes is decreased during
tGVHD. Consequently, tGVHD severity may be associated with
thymic function We studied the migration of alloreactive donor T
cells in vivo and found that donor T cells infiltrated the thymus
within the first week post-transplant. Upon adoptive transfer of
CFSE-labeled donor T cells we noted that thymus-infiltrating allor-
eactive donorT cells were fast-proliferating (CFSElo) and highly ac-
tivated (CD251CD441). We then analyzed T cell trafficking in
tGVHDwithmice deficient for certain traffickingmolecules, and as-
sessed tGVHD by loss of BM-derived CD41CD81 thymocytes.
We found that CCR9, b7 integrin, and PSGL1 were all partially re-
quired for tGVHD, while L-selectin and aE integrin may be dis-
pensable. Similarly, we examined the role of T cell cytolytic
pathways for tGVHD, and found that FasL and TRAIL were re-
quired for tGVHD, but that perforin andTNFwere dispensable. Fi-
nally, we assessed the role of various T cell regulatory molecules for
tGVHD, and found that Ceacam1 and OX40 were required, while
GITR was partially required and ICOS was dispensable. Host
non-hematopoietic thymic stroma may be an important target for
donor alloreactive T cells in GVH reaction models. We assessed
the expression of the death receptors Fas and DR5 in thymic stroma
fromnormal and irradiated (8.5Gy) BALB/cmice, and observed that
in particular, MHC class II-negative stroma (endothelial cells and fi-
broblasts), as well as a population of MHC class II-positive stroma
(epithelial cells) upregulated the expression of both Fas and DR5 af-
ter irradiation. Thymic epithelial cell numbers were relatively pre-
served after irradiation of mice deficient for TRAIL and FasL. In
conclusion, we found that TRAIL, TNF, CCR9, integrin b7,
PSGL1, Ceacam1 and OX40 on donor T cells as important for
tGVHD pathophysiology. These data suggest selective therapeutic
targets to attenuate tGVHD and improve post-transplant T-cell re-
constitution.345
ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE SCORING USING THE NIH
CONSENSUS CRITERIA
Treister, N.1,2, Stevenson, K.2, Kim, H.2, Cutler, C.2 1Brigham and
Women’s Hospital; 2Dana-Farber Cancer Institute
Background: The NIH Oral cGVHD Activity Assessment In-
strument is intended to be simple to use and to provide a reproducible
objective measure of disease activity over time. The objective of this
studywas to assess inter- and intra-observer variability in the compo-
nent and composite scores in patients evaluated with oral cGVHD.
